TY  - JOUR

T1  - Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

JO  - British Journal of Dermatology

PY  - 2020/09/24

AU  - Cork MJ

AU  - Thaçi D

AU  - Eichenfield LF

AU  - Arkwright PD

AU  - Sun X

AU  - Chen Z

AU  - Akinlade B

AU  - Boklage S

AU  - Guillemin I

AU  - Kosloski MP

AU  - Kamal MA et al

ED  - 

DO  - DOI: 10.1111/bjd.19460

PB  - Wiley

Y2  - 2024/12/22

ER  -